CA2473786A1 - Method of prophylaxis against large myocardial infarctions - Google Patents

Method of prophylaxis against large myocardial infarctions Download PDF

Info

Publication number
CA2473786A1
CA2473786A1 CA002473786A CA2473786A CA2473786A1 CA 2473786 A1 CA2473786 A1 CA 2473786A1 CA 002473786 A CA002473786 A CA 002473786A CA 2473786 A CA2473786 A CA 2473786A CA 2473786 A1 CA2473786 A1 CA 2473786A1
Authority
CA
Canada
Prior art keywords
nano
complement
grams
antibody
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002473786A
Other languages
English (en)
French (fr)
Inventor
Leonard Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2473786A1 publication Critical patent/CA2473786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002473786A 2002-01-22 2002-01-22 Method of prophylaxis against large myocardial infarctions Abandoned CA2473786A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/001694 WO2003061765A1 (en) 2002-01-22 2002-01-22 Method of prophylaxis against large myocardial infarctions

Publications (1)

Publication Number Publication Date
CA2473786A1 true CA2473786A1 (en) 2003-07-31

Family

ID=27608973

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002473786A Abandoned CA2473786A1 (en) 2002-01-22 2002-01-22 Method of prophylaxis against large myocardial infarctions

Country Status (4)

Country Link
EP (1) EP1467801A1 (ja)
JP (1) JP2006502089A (ja)
CA (1) CA2473786A1 (ja)
WO (1) WO2003061765A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
EP2374819B1 (en) 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2617920T3 (es) 2009-10-16 2017-06-20 Omeros Corporation Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2186108A1 (en) * 1994-03-23 1995-09-28 Scott A. Rollins Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation

Also Published As

Publication number Publication date
EP1467801A1 (en) 2004-10-20
WO2003061765A1 (en) 2003-07-31
JP2006502089A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
CA2454562A1 (en) Method of improving cognitive function
US7361339B2 (en) Methods for reducing morality associated with acute myocardial infarction
JP5873047B2 (ja) 溶血性疾患の処置方法
DK2359834T3 (en) Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
Zotz et al. Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PlA2) is a risk factor for bypass occlusion, myocardial infarction, and death
RU2020142517A (ru) Антитела к фактору xi и способы их применения
US20040081619A1 (en) Method of prophylaxis against large myocardial infarctions
JP2020504110A5 (ja)
RU2014106652A (ru) Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
RU2671955C2 (ru) Лечение сосудистого заболевания и его осложнений
Wever-Pinzon et al. Ventricular assist devices: pharmacological aspects of a mechanical therapy
CA2473786A1 (en) Method of prophylaxis against large myocardial infarctions
Zhou et al. HMGB1 neutralizing antibody attenuates cardiac injury and apoptosis induced by hemorrhagic shock/resuscitation in rats
AU2002239998A1 (en) Method of prophylaxis against large myocardial infarctions
AU2002320242A1 (en) Method of improving cognitive function
RU2649760C1 (ru) Способ лечения острого инфаркта миокарда с подъемом сегмента ST, осложненного кардиогенным шоком
US20060263358A1 (en) Method for reducing sepsis or cardiogenic shock associated with myocardial injury
US20230250166A1 (en) Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
Olson et al. Thrombocytosis as a Marker of Allograft Rejection in Lung Transplantation: A Case Series
Tinica et al. N-acetylcysteine for Prevention of Postoperative Renal Failure
Pavon et al. 5903 Fulminant Myocarditis treated with combined implantation of left and right percutaneous ventricular assist devices
Groseanu et al. A5. 9 Influence of vitamin D status on cardiovascular involvement in systemic sclerosis
Taal Mechanisms underlying progressive nephron injury in chronic kidney disease
Thoracic Thoracic and Cardiovascular Surgery
Gorsuch The immunological role of recombinant humanized cobra venom factor in mediating myocardial ischemia-reperfusion injuries

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20090122